Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

U. Coskun



Author of

  • +

    P1.22 - Poster Session 1 - Epidemiology, Etiology (ID 166)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Prevention & Epidemiology
    • Presentations: 1
    • +

      P1.22-002 - Non-small cell lung cancer in young patients: Clinicopathological features (ID 670)

      09:30 - 09:30  |  Author(s): U. Coskun

      • Abstract

      Background
      Non-small cell lung cancer (NSCLC) is the most common cancer worldwide. NSCLC is strongly related to age. Its incidence increases with advancing age and the median age at diagnosis is 70 years. Less than 5% of all NSCLC is seen before 40 years of age. Furthermore, young patients have different characteristics compared with older patients. In this study, the clinical features of patients less than 40 years of age were analyzed.

      Methods
      Medical records of patients diagnosed as having NSCLC between March 2000 and March 2013 were retrospectively examined in 17 institutions of Anatolian Society of Medical Oncology. Epidemiological data such as age, gender and smoking history was collected. Additionally, histological subtype, ECOG performance status, stage, number of organ metastasis, presence of cranial metastases were analyzed.

      Results
      A total of 210 patients were evaluated. Median age was 35 years (range, 18-40). The majority of the patients were males (148 males and 62 females). There were 120 patients with a history of smoking. Seventy-eight patients were non-smokers and twelve were unknown. Majority of the patients (64%) had stage IV disease at presentation. Most of the patients had good performance status. Half of these patients had two or more organ metastasis (53%). Cranial metastases were detected in 55 patients. Adenocarcinoma was the most common histological subtype (57%). Other subtypes were squamous cell carcinoma (20%) and unclassified (20%). In stage IV disease, adenocarcinoma was more frequent (64%). There was no association between histopathologic subtype and smoking history. Median overall survival (OS) of the entire cohort was 15.1 months. Median OS was similar to the literature data (stage II: 45.8 months, IIIA: 44.4 months, IIIB: 21.1 months and stage IV: 9.9 months).

      Conclusion
      Adenocarcinoma was more common in the younger patients. These patients had advanced disease and good performance status at presentation. However, survival was not better than older patients based on historical literature data.

  • +

    P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers (ID 165)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P2.06-006 - Clinical and Prognostic Importance of XIAP and USP8 in Advanced Stages of Non-Small Cell Lung Cancer (ID 669)

      09:30 - 09:30  |  Author(s): U. Coskun

      • Abstract

      Background
      Apoptotic pathways are controlled by activation or inhibition of the intracellular caspases. Inhibitor of apoptosis proteins (IAPs) are endogenous inhibitors of caspase activity. We aimed to investigate the relationship of the apoptosis regulators X-linked inhibitor of apoptosis (XIAP) and ubiquitin specific protease 8 (USP8) with clinical parameters, survival and response to chemotherapy in advanced stages of non-small cell lung cancer (NSCLC).

      Methods
      A total of 34 NSCLC patients (28 males, 6 females) and 44 healthy volunteers were included in the study. Most of the patients had squamous cell histology (62%), while others had adenocarcinoma (29%) and unclassified (8%) types. All patients had locally advanced stage IIIA-IIIB (50%) or metastatic (50%) disease. XIAP and USP8 levels were measured by ELISA method.

      Results
      The median serum XIAP levels were similar in patients and the controls (p=NS). USP8 level was higher in patients compared to the control group (p<0.0001). In univariate analysis, there was no significant relationship between XIAP and USP8 serum levels and age, sex, performance status, weight loss, stage of disease, histopatological type and response to chemotherapy. In the low and high XIAP and USP8 groups, there was no significant difference in progression-free survival (PFS) (p=0.432 and p=0.50, respectively) and overall survival (OS) (p=0.989 and p=0.90, respectively).

      Conclusion
      No relationship was found with serum XIAP and USP8 levels and clinical parameters, response to chemotherapy, PFS and OS in patients with advanced stages of NSCLC.